Protons against cancer: New research beamline for innovative radiotherapies
Prof. Dr Judith Reindl and PhD student Aikaterini Rousseti (from left to right) from the University of the Bundeswehr Munich present the experimental station for biological samples which is installed at the new Minibee beamline at HZB. © Kevin Fuchs / HZB
Magnetic quadrupoles focus the proton beam in front of the experiment platform. © Kevin Fuchs / HZB
Together with the University of the Bundeswehr Munich, the HZB has set up a new beamline for preclinical research. It will enable experiments on biological samples on innovative radiation therapies with protons.
The proton accelerator at the Helmholtz-Zentrum Berlin (HZB) has been used for about 25 years to combat certain types of eye tumours. So far, over 4800 people have benefited from proton eye tumour therapy, which is carried out in collaboration with Charité – Universitätsmedizin Berlin.
Now, the proton accelerator at HZB also offers the option of conducting preclinical research: A mini-beamline for preclinical experiments (Minibee) has been set up for this purpose together with the University of the Bundeswehr in Munich. The HZB's Proton Therapy Department has built the beam guidance and control system for the minibeams. The University of the Bundeswehr in Munich, with Prof. Judith Reindl from the Institute of Applied Physics and Measurement Technology and the Section of Biomedical Radiation Physics, installed a platform for image-guided irradiation of biological samples. This will enable joint experiments on radiobiology and innovative radiation therapy in the future.
‘At Minibee, we can use medical research to investigate how changes in parameters and settings of the proton beam affect the treatment,’ says Judith Reindl. Among other things, Minibee is designed to generate ultrashort proton flashes (FLASH therapy) or needle-fine radiation (beamlets). ‘Our aim is to develop new methods that effectively destroy tumours while providing even better protection for healthy tissue,’ says Prof. Dr. Andrea Denker, head of the Department of Proton Therapy at HZB.
arö
https://www.helmholtz-berlin.de/pubbin/news_seite?nid=28606;sprache=en
- Copy link
-
HZB and National University Kyiv-Mohyla Academy start cooperation in Energy and Climate
Helmholtz-Zentrum Berlin für Materialien und Energie GmbH (HZB) and the National University of "Kyiv-Mohyla Academy" (NaUKMA) have signed a Memorandum of Understanding (MoU). The MoU serves as the starting point for collaborative research, academic exchange, and capacity-building between the two institutions. Actions will be taken to establish the Joint Research and Policy Laboratory at NaUKMA in Kyiv. The aim of the future laboratory is to jointly develop research and policy analysis, focusing on the energy and climate dimensions of Ukraine’s EU integration.
-
MAX IV and BESSY II initiate new collaboration to advance materials science
Swedish national synchrotron laboratory MAX IV and Helmholtz-Zentrum Berlin (HZB) with BESSY II light source jointly announce the signing of a 5-year Cooperation Agreement. The new agreement establishes a framework to strengthen cooperation for operational and technological development in the highlighted fields of accelerator research and development, beamlines and optics, endstations and sample environments as well as digitalisation and data science.
-
Michael Naguib is visiting HZB as a Humboldt Research Awardee
Professor Michael Naguib, from Tulane University in the USA, is one of the discoverers of a new class of 2D materials: MXenes are characterised by a puff pastry-like structure and have many applications, such as in the production of green hydrogen or as storage media for electrical energy. During his Humboldt Research Award in 2025, Professor Naguib is working with Prof Volker Presser at the Leibniz Institute for New Materials in Saarbrücken and with Dr Tristan Petit at HZB.